These additional markers were identified in only one article within our systematic review, reporting the downregulation of MCAM (CD146) in glioblastoma 24, CLDN11 (claudin 11) in colon cancer 82, and TJP2 in melanoma and breast cancer 25. This evidence concerns the gene CLDN11 and breast carcinoma.